AbbVie Inc. (NYSE:ABBV) Shares Sold by Valley Brook Capital Group Inc.

Valley Brook Capital Group Inc. trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 0.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 22,699 shares of the company’s stock after selling 88 shares during the period. AbbVie makes up approximately 3.0% of Valley Brook Capital Group Inc.’s holdings, making the stock its 6th biggest holding. Valley Brook Capital Group Inc.’s holdings in AbbVie were worth $4,034,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Capital Advisors Inc. OK increased its holdings in shares of AbbVie by 1.6% during the 4th quarter. Capital Advisors Inc. OK now owns 335,011 shares of the company’s stock worth $59,531,000 after buying an additional 5,119 shares during the last quarter. Certuity LLC increased its holdings in shares of AbbVie by 82.8% during the 4th quarter. Certuity LLC now owns 11,964 shares of the company’s stock worth $2,126,000 after buying an additional 5,418 shares during the last quarter. Community Financial Services Group LLC increased its holdings in shares of AbbVie by 9.5% during the 4th quarter. Community Financial Services Group LLC now owns 2,687 shares of the company’s stock worth $477,000 after buying an additional 233 shares during the last quarter. Montz Harcus Wealth Management LLC increased its holdings in shares of AbbVie by 12.5% during the 4th quarter. Montz Harcus Wealth Management LLC now owns 2,204 shares of the company’s stock worth $392,000 after buying an additional 245 shares during the last quarter. Finally, Leavell Investment Management Inc. increased its holdings in shares of AbbVie by 0.8% during the 4th quarter. Leavell Investment Management Inc. now owns 79,674 shares of the company’s stock worth $14,158,000 after buying an additional 629 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Price Performance

NYSE ABBV opened at $191.81 on Wednesday. AbbVie Inc. has a 12 month low of $153.58 and a 12 month high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The firm has a market capitalization of $338.96 billion, a PE ratio of 79.92, a P/E/G ratio of 1.53 and a beta of 0.58. The company’s 50 day simple moving average is $177.71 and its 200 day simple moving average is $185.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same quarter last year, the business posted $2.79 EPS. As a group, equities research analysts forecast that AbbVie Inc. will post 12.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ABBV. Wolfe Research began coverage on AbbVie in a report on Friday, November 15th. They issued an “outperform” rating and a $205.00 price target for the company. JPMorgan Chase & Co. lowered their price target on AbbVie from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 13th. BMO Capital Markets increased their price target on AbbVie from $208.00 to $215.00 and gave the company an “outperform” rating in a report on Monday, February 3rd. Piper Sandler increased their price target on AbbVie from $212.00 to $220.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Finally, Piper Sandler Companies reiterated an “overweight” rating and issued a $220.00 price target on shares of AbbVie in a report on Tuesday, December 17th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $208.35.

Insider Activity at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.25% of the company’s stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.